Advances in methods for predicting phase i metabolism of polyphenols

Current Drug Metabolism

Volumn 15, Issue 1, 2014, Pages 120-126

  Melo Filho, Cleber Camilo ^a   Braga, Rodolpho C ^a,b   Andrade, Carolina H ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cytochrome P450; Docking; Flavonoids; Ligand based; Metabolism; Structure based

Indexed keywords

AMINO ACID; AURANTIIN; CYTOCHROME P450; DRUG METABOLIZING ENZYME; FLAVONOID; LIGAND; NARINGENIN; POLYPHENOL; QUERCETIN; RUTOSIDE;

ATHEROSCLEROSIS; COMPUTER MODEL; DRUG METABOLISM; DRUG STRUCTURE; ENZYME METABOLISM; METABOLITE; MOLECULAR DOCKING; NERVE DEGENERATION; REVIEW; TUMOR GROWTH;

ANIMALS; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; POLYPHENOLS; SOFTWARE;

EID: 84896370721     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200215666140130125339     Document Type: Review

References (53)

1. Cohen, S. D.; Kennedy, J. A. Plant metabolism and the environment: implications for managing phenolics. Crit. Rev. Food Sci. Nutr., 2010, 50, 620-43.
2. Van Dorsten, F. A.; Grün, C. H.; van Velzen, E. J. J.; Jacobs, D. M.; Draijer, R.; van Duynhoven, J. P. M. The metabolic fate of red wine and grape juice polyphenols in humans assessed by metabolomics. Mol. Nutr. Food Res., 2010, 54, 897-908.
3. Pan, M.-H.; Lai, C.-S.; Ho, C.-T. Anti-inflammatory activity of natural dietary flavonoids. Food Funct., 2010, 1, 15-31.
4. Côté, J.; Caillet, S.; Doyon, G.; Sylvain, J.-F.; Lacroix, M. Bioactive compounds in cranberries and their biological properties. Crit. Rev. Food Sci. Nutr., 2010, 50, 666-79.
5. Xiao, J.; Chen, T.; Cao, H.; Chen, L.; Yang, F. Molecular propertyaffinity relationship of flavanoids and flavonoids for HSA in vitro. Mol. Nutr. Food Res., 2011, 55, 310-7.
6. Beecher, G. R. Overview of dietary flavonoids: nomenclature, occurrence and intake. J. Nutr., 2003, 133, 3248S-3254S.
7. Quideau, S.; Deffieux, D.; Douat-Casassus, C.; Pouységu, L. Plant polyphenols: chemical properties, biological activities, and synthesis. Angew. Chem. Int. Ed. Engl., 2011, 50, 586-621.
8. Xiao, J.; Ni, X.; Kai, G.; Chen, X. A review on structure-activity relationship of dietary polyphenols inhibiting α-amylase. Crit. Rev. Food Sci. Nutr., 2013, 53, 497-506.
9. Deng, G.-F.; Xu, X.-R.; Zhang, Y.; Li, D.; Gan, R.-Y.; Li, H.-B. Phenolic compounds and bioactivities of pigmented rice. Crit. Rev. Food Sci. Nutr., 2013, 53, 296-306.
10. Andres, A.; Donovan, S. M.; Kuhlenschmidt, M. S. Soy isoflavones and virus infections. J. Nutr. Biochem., 2009, 20, 563-9.
11. Scalbert, A.; Williamson, G. Dietary Intake and Bioavailability of Polyphenols. J. Nutr., 2000, 130, 2073S-2085.
12. Vauzour, D.; Vafeiadou, K.; Rodriguez-Mateos, A.; Rendeiro, C.; Spencer, J. P. E. The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr., 2008, 3, 115-26.
13. Rathee, P.; Chaudhary, H.; Rathee, S.; Rathee, D.; Kumar, V.; Kohli, K. Mechanism of action of flavonoids as anti-inflammatory agents: a review. Inflamm. Allergy Drug Targets, 2009, 8, 229-35.
14. Arroo, R. R. J.; Androutsopoulos, V.; Beresford, K.; Ruparelia, K.; Surichan, S.; Wilsher, N.; Potter, G. A. Phytoestrogens as natural prodrugs in cancer prevention: dietary flavonoids. Phytochem. Rev., 2009, 8, 375-386.
15. Androutsopoulos, V. P.; Papakyriakou, A.; Vourloumis, D.; Tsatsakis, A. M.; Spandidos, D. A. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol. Ther., 2010, 126, 9-20.
16. Androutsopoulos, V. P.; Mahale, S.; Arroo, R. R. J.; Potter, G. Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation. Oncol. Rep., 2009, 21, 1525-8.
17. Kumar, G. N.; Surapaneni, S. Role of drug metabolism in drug discovery and development. Med. Res. Rev., 2001, 21, 397-411.
18. Nebert, D. W.; Dieter, M. Z. The evolution of drug metabolism. Pharmacology, 2000, 61, 124-135.
19. De Montellano, P. R. O. Cytochrome P450: Structure, Mechanism, and Biochemistry; Springer; Softcover reprint of hardcover 2nd ed. 1995 edition, 2010, p. 664.
20. Miners, J. O.; Birkett, D. J. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998, 45, 525-38.
21. Sousa, M. C. M.; Braga, R. R. C.; Cintra, B. A. S. B.; de Oliveira, V.; Andrade, C. H. In silico metabolism studies of dietary flavonoids by CYP1A2 and CYP2C9. Food Res. Int., 2013, 50, 102-110.
22. Jones, B. C.; Middleton, D. S.; Youdim, K. Cytochrome P450 metabolism and inhibition: analysis for drug discovery. Prog. Med. Chem., 2009, 47, 239-63.
23. Castro-Perez, J. M. Current and future trends in the application of HPLC-MS to metabolite-identification studies. Drug Discov. Today, 2007, 12, 249-56.
24. Stjernschantz, E.; Vermeulen, N. P. E.; Oostenbrink, C. Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450. Expert Opin. Drug Metab. Toxicol., 2008, 4, 513-27.
25. Braga, R. C.; Andrade, C. H. QSAR and QM/MM approaches applied to drug metabolism prediction. Mini Rev. Med. Chem., 2012, 12, 573-82.
26. Sun, H.; Scott, D. O. Structure-based drug metabolism predictions for drug design. Chem. Biol. Drug Des., 2010, 75, 3-17.
27. Rydberg, P.; Gloriam, D. E.; Zaretzki, J.; Breneman, C.; Olsen, L. SMARTCyp: A 2D Method for Prediction of Cytochrome P450- Mediated Drug Metabolism. ACS Med. Chem. Lett., 2010, 1, 96-100.
28. Rydberg, P.; Gloriam, D. E.; Olsen, L. The SMARTCyp cytochrome P450 metabolism prediction server. Bioinformatics, 2010, 26, 2988-9.
29. Carlsson, L.; Spjuth, O.; Adams, S.; Glen, R. C.; Boyer, S. Use of historic metabolic biotransformation data as a means of anticipating metabolic sites using MetaPrint2D and Bioclipse. BMC Bioinformatics, 2010, 11, 362.
30. Symyx Technologies Inc. 3100 Central Expressway Santa Clara, CA 95051.
31. Boyer, S.; Arnby, C. H.; Carlsson, L.; Smith, J.; Stein, V.; Glen, R. C. Reaction site mapping of xenobiotic biotransformations. J. Chem. Inf. Model., 2007, 47, 583-90.
32. Wang, R.; Lai, L.; Wang, S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J. Comput. Aided. Mol. Des., 2002, 16, 11-26.
33. Braga, R. C.; Alves, V. M.; Fraga, C. A. M.; Barreiro, E. J.; de Oliveira, V.; Andrade, C. H. Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone. J. Mol. Model., 2012, 18, 2065-78.
34. Sander, T.; Freyss, J.; von Korff, M.; Reich, J. R.; Rufener, C. OSIRIS, an entirely in-house developed drug discovery informatics system. J. Chem. Inf. Model., 2009, 49, 232-246.
35. Cavalla, D. Web Alert: Using the Internet for Medicinal Chemistry. In The Practice of Medicinal Chemistry; Wermuth, C., Ed.; Academic Press: Waltham, MA, 2008, pp. 255-289.
36. Registry of Toxic Effects of Chemical Substances. Accelrys Software, Inc. 2440 Camino Ramon, Suite 300 San Ramon, CA 94583.
37. Von Korff, M.; Sander, T. Toxicity-indicating structural patterns. J. Chem. Inf. Model., 2006, 46, 536-44.
38. OMEGA version 2.4.6. OpenEye Scientific Software, Inc., Santa Fe, NM, USA, http://www.eyesopen.com, 2012.
39. Hawkins, P. C. D.; Skillman, a G.; Warren, G. L.; Ellingson, B. a; Stahl, M. T. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J. Chem. Inf. Model., 2010, 50, 572-84.
40. Boström, J.; Greenwood, J. R.; Gottfries, J. Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J. Mol. Graph. Model., 2003, 21, 449-62.
41. Halgren, T. A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem., 1996, 17, 490-519.
42. QUACPAC version 1.5.0. OpenEye Scientific Software, Inc., Santa Fe, NM, USA, http://www.eyesopen.com, 2011.
43. OEDocking version 3.0.0. OpenEye Scientific Software, Inc., Santa Fe, NM, USA, http://www.eyesopen.com, 2012.
44. McGann, M. R.; Almond, H. R.; Nicholls, A.; Grant, J. A.; Brown, F. K. Gaussian docking functions. Biopolymers, 2003, 68, 76-90.
45. McGann, M. FRED and HYBRID docking performance on standardized datasets. J. Comput. Aided. Mol. Des., 2012, 26, 897-906.
46. McGann, M. FRED pose prediction and virtual screening accuracy. J. Chem. Inf. Model., 2011, 51, 578-96.
47. Wester, M. R.; Yano, J. K.; Schoch, G. a; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F.; Papers, J. B. C.; Doi, M. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J. Biol. Chem., 2004, 279, 35630-7.
48. Da Silva, E. L.; Piskula, M. K.; Yamamoto, N.; Moon, J. H.; Terao, J.; Silva, E. L. Quercetin metabolites inhibit copper ion-induced lipid peroxidation in rat plasma. FEBS Lett., 1998, 430, 405-8.
49. Hosny, M.; Dhar, K.; Rosazza, J. P. N. Hydroxylations and Methylations of Quercetin, Fisetin, and Catechin by Streptomyces g riseus. J. Nat. Prod., 2001, 64, 462-465.
50. Breinholt, V. M.; Offord, E. a; Brouwer, C.; Nielsen, S. E.; Brøsen, K.; Friedberg, T. In vitro investigation of cytochrome P450- mediated metabolism of dietary flavonoids. Food Chem. Toxicol., 2002, 40, 609-16.
51. Hodek, P.; Trefil, P.; Stiborová, M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 2002, 139, 1-21.
52. Rice-Evans, C. Flavonoid antioxidants. Curr. Med. Chem., 2001, 8, 797-807.
53. Kagawa, H.; Takahashi, T.; Ohta, S.; Harigaya, Y. Oxidation and rearrangements of flavanones by mammalian cytochrome P450. Xenobiotica, 2004, 34, 797-810.